financetom
Business
financetom
/
Business
/
Marvell Issues Revenue Outlook Below Estimates; Fiscal Second-Quarter Results Match Street Views
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Marvell Issues Revenue Outlook Below Estimates; Fiscal Second-Quarter Results Match Street Views
Aug 29, 2025 3:53 AM

06:38 AM EDT, 08/29/2025 (MT Newswires) -- Marvell Technology ( MRVL ) shares dropped early Friday as the semiconductor solutions provider issued a fiscal third-quarter revenue outlook below market estimates at the midpoint and reported results for the previous three-month period in line with expectations.

The company anticipates revenue to be at $2.06 billion, plus or minus 5%, for the ongoing quarter, it said late Thursday. The current consensus on FactSet is for revenue of $2.09 billion. Adjusted earnings are pegged at $0.74 per share, plus or minus $0.05, while the Street is looking for $0.73.

The stock tumbled 13% in the most recent premarket activity.

The guidance includes mid-single-digit million-dollar revenue contribution from the company's automotive ethernet business before its divestiture in August, Chief Financial Officer Willem Meintjes said during an earnings call, according to a FactSet transcript. The business would have added roughly $60 million to the firm's outlook if it had operated it for the full quarter, Meintjes said.

"We expect revenue from our electro-optics products to grow double-digits sequentially on a percentage basis as we continue to benefit from our market-leading position in (artificial intelligence) interconnect," Chief Executive Matt Murphy said on the call.

The firm's custom business "remains on track" to grow in the second half, but that growth is projected to be "nonlinear" with the fourth quarter "substantially stronger than the third," Murphy said. "As a result, we expect overall data center revenue in the third quarter to be flat sequentially, with electro-optics strength offset by lower custom revenue," the CEO added.

For the three months through Aug. 2, Marvell's ( MRVL ) adjusted EPS advanced to $0.67 from $0.30 the year before, meeting the average analyst estimate on FactSet. Revenue jumped 58% year over year to $2.01 billion, largely in line with the market view.

Revenue from the data center segment surged 69% to $1.49 billion, buoyed by robust AI demand, Murphy said on the call. Automotive and industrial revenue came in at $76 million, compared with $76.2 million in the prior-year quarter.

Sales in the carrier infrastructure division soared 71% year over year to $130.1 million, while enterprise networking inclined to $193.6 million from $151 million. Consumer revenue climbed by 30% to $115.9 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BMO on The Day Ahead in Canada
BMO on The Day Ahead in Canada
Dec 6, 2024
07:33 AM EST, 12/06/2024 (MT Newswires) -- Canada will release its Labour Force Survey (LFS) for November at 8:30 a.m. ET on Friday, noted Bank of Montreal (BMO). Canadian employment growth is expected to improve to 20,000 in November -- consensus at 25,000 -- after slowing to 14,500 in October, noted the bank. Annual average hourly wage gains look to...
Update: Encompass Health, Enhabit Win Breach of Fiduciary Duty Lawsuit
Update: Encompass Health, Enhabit Win Breach of Fiduciary Duty Lawsuit
Dec 6, 2024
07:34 AM EST, 12/06/2024 (MT Newswires) -- (Updates to add Nautic and Vistria Group's joint statement in the fifth paragraph and the recent stock movement in the seventh paragraph.) Encompass Health ( EHC ) and Enhabit ( EHAB ) said Wednesday the Delaware Court of Chancery awarded them damages and other remedies related to a lawsuit against former executives and...
AstraZeneca's Imfinzi Granted Priority Review in US as Muscle-Invasive Bladder Cancer Treatment
AstraZeneca's Imfinzi Granted Priority Review in US as Muscle-Invasive Bladder Cancer Treatment
Dec 6, 2024
07:35 AM EST, 12/06/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Friday that the US Food and Drug Administration granted priority review for a supplemental biologics license application for Imfinzi as a treatment for patients with muscle-invasive bladder cancer. The company said a priority review is granted to applications for medicines that would offer significant improvements over other treatment...
CRH Names Alan Connolly Interim CFO
CRH Names Alan Connolly Interim CFO
Dec 6, 2024
07:30 AM EST, 12/06/2024 (MT Newswires) -- CRH (CRH) said Friday it has named Alan Connolly interim chief financial officer, effective Jan. 1. Connolly will succeed current CFO Jim Mintern, who will assume the chief executive role, the company said. Connolly was previously the director of strategic finance, said CRH, which is actively searching for a permanent successor. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved